Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» MS
MS
Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff
Endpoints
Tue, 02/13/18 - 09:11 am
Novartis
Momenta Pharmaceuticals
FDA
Copaxone
Teva Pharmaceutical
Glatopa
MS
multiple sclerosis
Will Teva Pharmaceutical's Pain Be Mylan's Gain?
Motley Fool
Fri, 02/9/18 - 09:33 am
Teva Pharmaceutical
Mylan Labs
Copaxone
generics
MS
multiple sclerosis
Multiple Sclerosis Drug Could be Safer for Patients if Dosing Intervals are Extended, Says Study
Xtalks
Tue, 02/6/18 - 09:25 am
MS
multiple sclerosis
dosing
PML
Roche granted approval for ocrelizumab (multiple sclerosis) in Europe
GoinPharma
Sat, 01/13/18 - 10:48 pm
Roche
ocrelizumab
Europe
MS
multiple sclerosis
Look out, Teva: Mylan's Copaxone copy has already captured serious share
Fierce Pharma
Thu, 01/4/18 - 10:10 pm
Teva Pharmaceutical
Mylan Labs
Copaxone
generics
MS
multiple sclerosis
Biogen set to raise $300M from New Year's price hikes, just enough to offset MS competition
Fierce Pharma
Thu, 01/4/18 - 12:14 am
Biogen
MS
multiple sclerosis
drug pricing
Biogen inks outcomes-based contract for MS meds
BioPharma Dive
Thu, 12/7/17 - 09:05 am
Biogen
MS
multiple sclerosis
Prime Therapeutics
PBMs
Most Impressive Drug Launch: Roche's Ocrevus
BioPharma Dive
Mon, 12/4/17 - 11:41 am
Roche
Ocrevus
drug launches
MS
multiple sclerosis
Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership
Marketwatch
Mon, 11/27/17 - 09:10 am
Alkermes
Biogen
MS
multiple sclerosis
ALKS 8700
Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal
Endpoints
Thu, 11/9/17 - 12:02 pm
Sanofi
multiple sclerosis
MS
Principia Biopharma
How Aubagio became the most switched-to oral MS drug
Medical Marketing and Media
Tue, 10/31/17 - 10:02 am
Aubagio
MS
multiple sclerosis
Sanofi
Late-stage ozanimod data brings Celgene closer to filing
BioPharma Dive
Mon, 10/30/17 - 02:56 pm
ozanimod
Celgene
MS
multiple sclerosis
Bloodied Celgene posts promising ozanimod PhIII MS data, but is it really a $6 billion drug?
Endpoints
Mon, 10/30/17 - 09:56 am
Celgene
ozaminod
MS
multiple sclerosis
[forum discussion]Should rank reports be eliminated?
Cafepharma Message Boards
Thu, 10/12/17 - 09:26 am
drug reps
MS
multiple sclerosis
Genentech
FDA offers surprise OK for Mylan’s Copaxone knockoffs, slamming Teva
Endpoints
Wed, 10/4/17 - 12:17 pm
FDA
Mylan Labs
Copaxone
Teva Pharmaceutical
MS
multiple sclerosis
After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine
Endpoints
Fri, 08/25/17 - 09:57 am
Merck KGaA
MS
multiple sclerosis
cladribine
Drug blocked by European regulators improves quality of life for MS patients
Drug Delivery Business News
Fri, 08/18/17 - 12:09 pm
Europe
MS
multiple sclerosis
cladribine
Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers
Fierce Pharma
Thu, 08/17/17 - 11:48 pm
multiple sclerosis
MS
drug pricing
Bayer
Biogen
Merck KGaA
Novartis
Sanofi
Teva Pharmaceutical
Roche
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
Fri, 07/21/17 - 10:25 am
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
How Biogen Inc. Makes Most of Its Money
Motley Fool
Thu, 07/13/17 - 05:43 pm
Biogen
Tecfidera
Tysabri
MS
multiple sclerosis
Pages
« first
‹ previous
…
6
7
8
9
10
11
12
13
14
…
next ›
last »